A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
Latest Information Update: 05 Sep 2022
At a glance
- Drugs KBP-V001 (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Kentucky BioProcessing
Most Recent Events
- 14 Sep 2021 Status changed from active, no longer recruiting to completed.
- 30 Aug 2021 Planned primary completion date changed from 31 Jul 2021 to 31 Aug 2021.
- 29 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.